Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma

Indian Journal of Pharmacology

Volumn 46, Issue 3, 2014, Pages 334-336

  Sil, Amrita ^a   Das, Nilay Kanti ^b  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Hand foot syndrome; Renal cell carcinoma; Sorafenib

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; CLOBETASOL; CORTICOSTEROID; EMOLLIENT AGENT; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

ABNORMAL LABORATORY RESULT; ADRENALECTOMY; ADULT; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DRUG DOSE REDUCTION; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; NEPHRECTOMY; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; HAND-FOOT SYNDROME; KIDNEY NEOPLASMS;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HAND-FOOT SYNDROME; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS;

EID: 84901392667     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.132189     Document Type: Article

References (11)

1. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009;60:299-305.
2. Demirçay Z, Gürbüz O, Alpdoǧan T, Yücelten D, Alpdoǧan O, Kurtkaya O, et al. Chemotherapy-induced acral erythema in leukemic patients: A report of 15 cases. Int J Dermatol 1997;36:593-8.
3. McLellan B, Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatol Ther 2011;24:396-400.
4. The use of the WHO-UMC system for standardized case causality assessment [monograph on the Internet]. Uppsala: The Uppsala Monitoring Centre; 2005. Available from: http://www.who-umc.org/graphics/4409.pdf [Last accessed on 2013 Jul 16].
5. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
6. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992;49:2229-32.
7. Gomez P, Lacouture ME. Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: Experience in breast cancer. Oncologist 2011;16:1508-19.
8. Lee JH, Chung YH, Kim JA, Shim JH, Lee D, Lee HC, et al. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer 2013;119:136-42.
9. Lountzis NI, Maroon MS. Sorafenib-induced palmoplantar hyperkeratosis. J Drugs Dermatol 2008;7:588-9.
10. Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC. Hand-foot skin reaction in patients treated with sorafenib: A clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008;158:592-6.
11. Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009;15:1411-6.